• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Shattuck Labs Inc.

    12/4/24 9:00:29 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STTK alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001425738
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Shattuck Labs, Inc.
    SEC File Number
    001-39593
    Address of Issuer
    500 W. 5th Street
    Austin
    TEXAS
    78701
    Phone
    512-900-4690
    Name of Person for Whose Account the Securities are To Be Sold
    Redmile Group, LLC
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director, 10% Stockholder

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock, $0.0001 par value(1)
    Jefferies LLC
    520 Madison Avenue
    New York � NY � 10022
    133371150709.234773970812/04/2024
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock, $0.0001 par value(1)10/14/2020Open Market Purchases or Purchases in Public OfferingPurchased in open market transactions or from Issuer in Public OfferingCheckbox not checked13337110/14/2020Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    (1) The total number of shares of Common Stock that may be sold represents shares that may be sold on an aggregate basis by private investment vehicles managed by Redmile Group, LLC, as follows: Redmile Capital Offshore Fund (ERISA), Ltd. - 42,498 shares; Redmile Strategic Trading Sub, Ltd. - 17,349 shares; and Redmile Strategic Long Only Trading Sub, Ltd. - 73,524 shares. (2) Redmile Group, LLC is the investment manager of Redmile Capital Offshore Fund (ERISA), Ltd., Redmile Strategic Trading Sub, Ltd. and Redmile Strategic Long Only Trading Sub, Ltd.
    Date of Notice
    12/04/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Jennifer Ciresi, General Counsel and Chief Compliance Officer, Redmile Group, LLC(2)

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $STTK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STTK

    DatePrice TargetRatingAnalyst
    3/17/2025$4.00Outperform
    Leerink Partners
    10/2/2024$8.00 → $2.00Buy → Neutral
    Citigroup
    10/2/2024Buy → Hold
    Needham
    10/1/2024Buy → Neutral
    H.C. Wainwright
    6/17/2024Buy → Neutral
    BTIG Research
    8/31/2022$12.00Buy
    BTIG Research
    6/1/2022$13.00Buy
    Citigroup
    5/2/2022$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $STTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Shattuck Labs Inc.

      SC 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

      12/6/24 9:03:38 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

      SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)

      11/13/24 8:30:26 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

      SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)

      11/12/24 5:01:20 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STTK
    Leadership Updates

    Live Leadership Updates

    See more
    • Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

      AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors, effective March 1, 2024. Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck. "It is a pleasure to welcome Clay and Kate, esteemed industry leaders, to our Board of Directors," said Taylor Schre

      3/4/24 7:00:00 AM ET
      $IMNM
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023

      AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its third-quarter 2023 financial results and provide a general business overview on Thursday, November 9, 2023. Title: Shattuck Labs Third-Quarter 2023 Earnings Call Speakers: Taylor Schreiber, CEO; Andrew Neill, CFO; Lini Pandite, CMO Date & Time: Thursday, November 9, 2023 at 8:00 a.m. ET Dial-in Details: Toll-Free Dial-In Number: 1 (888) 440-4368 To

      11/6/23 9:28:40 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs Announces Changes to its Board of Directors

      AUSTIN, TX and DURHAM, NC, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced the appointment of Dr. Carrie Brownstein, M.D., to its Board of Directors. Dr. Brownstein currently serves as the Chief Medical Officer at Cellectis. She will replace Josiah Hornblower, Shattuck's Chairman and founder, who is stepping down from the Board of Directors. George Golumbeski, Ph.D., has been appointed Chairman of the

      10/28/21 4:30:00 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STTK
    SEC Filings

    See more
    • SEC Form 10-Q filed by Shattuck Labs Inc.

      10-Q - Shattuck Labs, Inc. (0001680367) (Filer)

      5/1/25 4:28:54 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Shattuck Labs, Inc. (0001680367) (Filer)

      5/1/25 4:21:31 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Shattuck Labs Inc.

      10-K/A - Shattuck Labs, Inc. (0001680367) (Filer)

      5/1/25 4:14:05 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STTK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – Company advances SL-325 program with an IND filing expected in the third quarter of 2025 – – Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, May 01, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025 and provided recent business highlights. "All IND-enabling activities and regulatory interactions rem

      5/1/25 4:20:00 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

      AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one-on-one meetings at the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025. Conference DetailsFormat: Presentation and one-on-one meetingsPresenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive OfficerDate: April 9, 2025Time: 3:00 PM EDTWebcast link: HERE A

      4/2/25 5:00:00 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

      – Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A; data demonstrated favorable safety profile, full receptor occupancy, lack of DR3 agonism – – SL-325 advances toward Phase 1; on track for IND filing in the third quarter of 2025 – – Cash balance of approximately $73.0 million as of December 31, 2024, expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, March 27, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneerin

      3/27/25 7:00:00 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Shattuck Labs with a new price target

      Leerink Partners initiated coverage of Shattuck Labs with a rating of Outperform and set a new price target of $4.00

      3/17/25 7:44:03 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs downgraded by Citigroup with a new price target

      Citigroup downgraded Shattuck Labs from Buy to Neutral and set a new price target of $2.00 from $8.00 previously

      10/2/24 7:58:39 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs downgraded by Needham

      Needham downgraded Shattuck Labs from Buy to Hold

      10/2/24 7:40:05 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technical Officer Shukla Abhinav A. covered exercise/tax liability with 2,261 shares, decreasing direct ownership by 3% to 73,536 units (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      1/28/25 6:13:29 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Business Officer Deyoung Casi covered exercise/tax liability with 2,297 shares, decreasing direct ownership by 3% to 81,465 units (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      1/28/25 6:08:41 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Pandite Arundathy N. covered exercise/tax liability with 3,211 shares, decreasing direct ownership by 2% to 206,265 units (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      1/28/25 6:04:53 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STTK
    Financials

    Live finance-specific insights

    See more
    • Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

      – Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further development of SL-172154 discontinued –   – Prioritization to focus on SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A, intended for clinical development in inflammatory bowel disease (IBD); IND filing expected in Q3 2025 – – SL-172154 associated restructuring expected to extend cash runway into 2027 – – Company to host investor call today at 8:00 AM Eastern Time (ET) – AUSTIN, T

      10/1/24 6:30:00 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

      – Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% ORR in frontline TP53m AML patients, 33% CR/complete remission with incomplete hematologic recovery (CRi) and median overall survival had not yet been reached – – SL-172154 demonstrated a manageable interim safety profile in combination with AZA – – Focuses clinical development opportunity in HR-MDS and TP53m AML; these indications may offer the fastest path to potential approval; enrollment underway in randomized, controlled HR-MDS co

      6/14/24 6:00:00 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

      - Conference call and webcast to be held June 14, 2024 at 7:30 a.m. ET featuring lead investigator - AUSTIN, TX and DURHAM, NC, June 06, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will host an investor call for an interim safety and efficacy update from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in HR-MDS and TP53m AML, being presented at the EHA 2024 Congress. The event will feature lead investigator, Dr. Naval G. Dave

      6/6/24 7:30:00 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Redmile Group, Llc sold $166,714 worth of shares (133,371 units at $1.25), bought $166,714 worth of shares (133,371 units at $1.25), disposed of $1,283,610 worth of shares (1,026,888 units at $1.25) and acquired $1,283,610 worth of shares (1,026,888 units at $1.25) (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      12/6/24 9:00:15 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Schreiber Taylor bought $44,220 worth of shares (36,500 units at $1.21), increasing direct ownership by 106% to 71,002 units (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      10/8/24 6:05:12 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Brous Tyler bought $32,768 worth of shares (8,416 units at $3.89), increasing direct ownership by 4% to 238,088 units (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      7/1/24 6:30:02 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care